{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:46:16Z","timestamp":1791179176741,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T00:00:00Z","timestamp":1394582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Although initial rituximab\u2010containing chemotherapies achieve high response rates, indolent B\u2010cell non\u2010Hodgkin lymphoma (B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>), such as follicular lymphoma (<jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>), is still incurable. Therefore, new effective agents with novel mechanisms are anticipated. In this multicentre phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study, patients with relapsed\/refractory indolent B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> and mantle cell lymphoma (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>) received vorinostat 200\u00a0mg twice daily for 14 consecutive days in a 21\u2010d cycle until disease progression or unacceptable toxicity occurred. The primary endpoint was overall response rate (<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>) in <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content> patients and safety and tolerability in all patients. Secondary endpoints included progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>). Fifty\u2010six eligible patients were enrolled; 50 patients (39 with <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>, seven with other B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>, and four with <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>) were evaluable for <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>, and 40 patients had received rituximab\u2010containing prior chemotherapeutic regimens. For the 39 patients with <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>, the <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> was 49% [95% confidence interval (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>): 32\u00b74, 65\u00b72] and the median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> was 20\u00a0months (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 11\u00b72, 29\u00b77). Major toxicities were manageable grade 3\/4 thrombocytopenia and neutropenia. Vorinostat offers sustained antitumour activity in patients with relapsed or refractory <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content> with an acceptable safety profile. Further investigation of vorinostat for clinical efficacy is warranted.<\/jats:p>","DOI":"10.1111\/bjh.12819","type":"journal-article","created":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T06:36:50Z","timestamp":1394606210000},"page":"768-776","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["A multicentre phase <scp>II<\/scp> study of vorinostat in patients with relapsed or refractory indolent B\u2010cell non\u2010Hodgkin lymphoma and mantle cell lymphoma"],"prefix":"10.1111","volume":"165","author":[{"given":"Michinori","family":"Ogura","sequence":"first","affiliation":[{"name":"Department of Haematology and Oncology Nagoya Daini Red Cross Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology Tokai University School of Medicine Isehara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology Nagoya Daini Red Cross Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Clinical Research, Innovation and Education Centre Tohoku University Hospital Sendai Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Dong\u2010A University College of Medicine Busan South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology National Cancer Centre Hospital East Kashiwa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Haematology and Cell Therapy Department of Clinical Trials Aichi Cancer Centre Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Yan","family":"Au","sequence":"additional","affiliation":[{"name":"University Medical Unit Queen Mary Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwei\u2010Fang","family":"Tien","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Matsuno","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology Hokkaido University Hospital Sapporo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Terauchi","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Radiology National Cancer Centre Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Japan Development MSD K.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Mori","sequence":"additional","affiliation":[{"name":"Japan Development MSD K.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Japan Development MSD K.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shimamoto","sequence":"additional","affiliation":[{"name":"Japan Development MSD K.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"Department of Haematology National Cancer Centre Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Haematology\u2010Oncology Department of Medicine Samsung Medical Centre Sungkyunkwan University School of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0344"},{"key":"e_1_2_7_3_1","first-page":"177","article-title":"Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects","volume":"32","author":"Carlisi D.","year":"2008","journal-title":"International Journal of Oncology"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.10.082"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24714"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.1398"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10351"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.04077"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01635.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2434"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09730"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1693"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_7_15_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.9313"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01703.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1096\/fj.02-1003fje","article-title":"Tumor cell\u2010selective cytotoxicity by targeting cell cycle checkpoints","volume":"17","author":"Warrener R.","year":"2003","journal-title":"FASEB Journal"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01360.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8508"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"}],"updated-by":[{"DOI":"10.1111\/bjh.13012","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,7,25]],"date-time":"2014-07-25T00:00:00Z","timestamp":1406246400000}}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12819","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12819","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.12819","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:03:44Z","timestamp":1696316624000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1111\/bjh.12819"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12819","archive":["Portico"],"relation":{"erratum":[{"id-type":"doi","id":"10.1111\/bjh.13012","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,12]]},"assertion":[{"value":"2013-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-12-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}